Myeloproliferative Neoplasm Treatment: What Patients Need to Know

Assessing Cardiovascular Risk in Essential Thrombocythemia

How Is Cardiovascular Risk Assessed in Patients with ET?

How is cardiovascular risk assessed in patients with essential thrombocythemia (ET), and what are the treatment options? Follow along as Jeanne Palmer, MD, from Mayo Clinic Arizona explains some of the standard risk factors such as blood pressure, diabetes, cholesterol, and family history, and how they can inform treatment choice. Dr. Palmer also discusses aspirin dosing and how it is managed.

Support for this series has been provided by Incyte. Patient Power maintains complete editorial control and is solely responsible for program content.

© 2024 HealthCentral LLC. All rights reserved.

Myeloproliferative Neoplasm Treatment: What Patients Need to Know